US OptionsDetailed Quotes
BIOR240719P2500
- 1.80
- 0.000.00%
15min DelayClose Jul 12 16:00 ET
0.00High0.00Low
1.80Open1.80Pre Close0 Volume8 Open Interest2.50Strike Price0.00Turnover501.92%IV-3.40%PremiumJul 19, 2024Expiry Date1.82Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9734Delta0.1708Gamma0.37Leverage Ratio-0.0017Theta-0.0002Rho-0.36Eff Leverage0.0000Vega
Biora Therapeutics Stock Discussion
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
BIVI(.49) I think has bottomed at .42 - Good adds here at .40s for a run to $1. Has a large gap to $1.76 which is high target. Can use the .42 as a safety for stop loss
BIOR(.70) Filed for mixed shelf offering two weeks ago, been trying to find these…HC Wainwright has $15 Target on it, don’t believe it but I do like it for gap fill to 1.08 minimum. I think this is going to get ran up and offering dropped. Should get dips t...
Don't know who's setting stop losses on a stock like this, but I'm glad they got stopped out today. People often say "I wish I'd bought Apple back in the '80s!" but got no stomach for the days like today, ones that would've scared them out before Apple became a juggernaut.
NEWS
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
No comment yet